Sugi Predict

Sugi Predict / Compounds / SCHEMBL1421745

SCHEMBL1421745

SCHEMBL1421745

CC(C)(C(=O)O)c1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 1/20 0.49
▸ MAPT P10636 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ XBP1 P17861 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ KCNN4 O15554 4/20 0.48
▸ AKR1C3 P42330 2/20 0.47
▸ AKR1C2 P52895 2/20 0.47
▸ HSD11B1 P28845 1/20 0.42
▸ CES2 O00748 1/20 0.41
▸ CES1 P23141 1/20 0.41
▸ S1PR2 O95136 3/20 0.40
▸ BCL2L1 Q07817 1/20 0.40
▸ BAD Q92934 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3497043 0.88 MAPT (0.52) APPMAPTKMT2AAKR1C3AKR1C2
SCHEMBL23003615 0.84 KCNN4 (0.50) MAPTKMT2AMEN1NPC1XBP1
Ethyl Acetate SCHEMBL28032347 0.83 LMNA (0.44) APPMAPTKMT2AMEN1NPC1
SCHEMBL16877062 0.83 KMT2A (0.46) MAPTKMT2AMEN1NPC1XBP1
SCHEMBL1626471 0.82 APP (0.62) APPMAPTKMT2ANPC1HTT
SCHEMBL9768982 0.82 KMT2A (0.48) MAPTKMT2AMEN1NPC1XBP1
SCHEMBL27609150 0.82 NPC1 (0.48) MAPTKMT2AMEN1NPC1XBP1
SCHEMBL7694323 0.82 NPC1 (0.48) MAPTKMT2AMEN1NPC1XBP1
SCHEMBL4664901 0.81 SRD5A2 (0.54) APPMAPTKMT2AMEN1NPC1
SCHEMBL19285761 0.81 APP (0.49) APPAKR1C3AKR1C2BCL2L1BAD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099466-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2026-05-15 — — WO disclosed
EP-4702033-A1 DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF Imhotex Limited (GB) 2026-03-04 — — EP disclosed
US-20250340528-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-11-06 — — US disclosed
US-12459920-B2 Targeted protein degradation MONTE ROSA THERAPEUTICS AG (CH) 2025-11-04 — — US disclosed
WO-2025224463-A1 DESMURAMYLPEPTIDE ANALOGUE MONOESTER Imhotex Limited (GB) 2025-10-30 — — WO disclosed
US-20250302803-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES UNIVERSITY OF HOUSTON SYSTEM (US) 2025-10-02 — — US disclosed
US-20250243180-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-07-31 — — US disclosed
US-12357610-B2 Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures UNIVERSITY OF HOUSTON SYSTEM (US) 2025-07-15 — — US disclosed
CN-120118863-A Cytochrome P450 monooxygenase and application thereof 遵义医科大学 2025-06-10 — — CN disclosed
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 — — WO disclosed
CN-101296904-A Amide derivatives as kinase inhibitors DEVGEN NV (BE) 2008-10-29 — — CN disclosed
WO-2008076427-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 — — WO disclosed
WO-2008070707-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-06-12 — — WO disclosed
WO-2008070707-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-06-12 — — WO disclosed
EP-1907361-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS Devgen N.V. (BE) 2008-04-09 — — EP disclosed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 — — US disclosed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 — — US disclosed
WO-2007130499-A2 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-11-15 — — WO disclosed
WO-2007006546-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS DEVGEN N.V. (BE) 2007-01-18 — — WO disclosed
US-5675034-A Process for preparing 2-(p-fluorophenyl)-2 methyl-propionic acid and 3-(p-fluorophenyl)-2-methylpropionic acid derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1997-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243180-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 APP 325/4885MAPT 389/4885KMT2A 3318/4885
US-12459920-B2 Targeted protein degradation NEK7, NEK1, RIPK1 APP 323/4885MAPT 383/4885KMT2A 3301/4885
US-12357610-B2 Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures AADAC, GABRB2, GABARAPL2 APP 260/4885MAPT 1500/4885KMT2A 1290/4885
US-20070287699-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 APP 4883/4885MAPT 4635/4885KMT2A 4280/4885
US-20250302803-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES AADAC, GABRB2, GABARAPL2 APP 260/4885MAPT 1500/4885KMT2A 1290/4885
US-20250340528-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 APP 325/4885MAPT 389/4885KMT2A 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.